Ticker Symbol: YMAB
Y-Mabs Therapeutics Inc
$18.95 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Currency:
USD
Asset
Type: Common Stock
CIK:0001722964
Company Profile
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: www.ymabs.com
CEO: N/A
Tags:
- Health Technology
- Pharmaceuticals: Major
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $5.15
Change:
-$0.20
(
-3.74%)
Days Range: $5.07 - $5.38
Beta: 2.04
52wk. High: $15.89
52wk. Low: $2.70
Ytd. Change 5.89%
50 Day Moving Average: $5.22
200 Day Moving Average: $6.52
Shares Outstanding: 43620192
Valuation
Market Cap: 22.5B
PE Ratio: -
EPS (TTM): -0.8942
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A